Significant association of pre-existing asthma with an increased risk for ICU admission among COVID-19 patients: Evidence based on a meta-analysis

Han, Xueya; Xu, Jie; Hou, Hongjie; Yang, Haiyan; Wang, Yadong

doi:10.1016/j.jinf.2021.11.021

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hospitalization rate of allergic asthmatics was 50% lower compared to non‐allergic asthmatics 135 . A recent meta‐analysis identified preexisting asthma as a risk factor for intensive care unit (ICU) admission among COVID‐19 patients 140 . The heterogeneity of asthma endotypes (allergic vs. non‐allergic asthma) may underly the different disease course in these studies 36,135 .…”

Section: Covid‐19 and Asthmamentioning

confidence: 95%

“… 135 A recent meta‐analysis identified preexisting asthma as a risk factor for intensive care unit (ICU) admission among COVID‐19 patients. 140 The heterogeneity of asthma endotypes (allergic vs. non‐allergic asthma) may underly the different disease course in these studies. 36 , 135 Eosinopenia was associated with worse outcomes of COVID‐19, including longer duration of hospitalization, higher severity, and mortality.…”

Section: Covid‐19 and Asthmamentioning

confidence: 98%

See 1 more Smart Citation

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy of the COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID-19.

show abstract

Section: Covid‐19 and Asthmamentioning

confidence: 95%

Section: Covid‐19 and Asthmamentioning

confidence: 98%

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

show abstract

“…The hospitalization rate of allergic asthmatics was 50% lower compared to non-allergic asthmatics 110 . A recent meta-analysis identified preexisting asthma as a risk factor for intensive care unit (ICU) admission among COVID-19 patients 114 . The heterogeneity of asthma endotypes (allergic vs. nonallergic asthma) may underly the different disease course in these studies 35,110 .…”

Section: Covid-19 and Asthmamentioning

confidence: 99%

Recent developments in the immunopathology of COVID-19

Gao

Zhang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of COVID-19 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4 and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) has been identified as an important cause of death of children with COVID-19. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. Atopic diseases, such as allergic asthma and rhinitis, have been shown to be associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, EAACI developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging SARS-CoV-2 variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID.

show abstract

Genetic variation of allergic disease is associated with the susceptibility to COVID-19

Gao

Zhu

et al. 2022

Journal of Infection

View full text Add to dashboard Cite

Significant association of pre-existing asthma with an increased risk for ICU admission among COVID-19 patients: Evidence based on a meta-analysis

Cited by 4 publications

References 9 publications

Recent developments in the immunopathology of COVID‐19

Recent developments in the immunopathology of COVID‐19

Recent developments in the immunopathology of COVID-19

Genetic variation of allergic disease is associated with the susceptibility to COVID-19

Contact Info

Product

Resources

About